Molbio Diagnostics Limited (NSE: MOLBIO) and QMS Medical Allied Services Limited (NSE: QMSMEDI) are both listed in the Medical Testing, Analyzing, and Diagnostic Equipment industry. Molbio Diagnostics has a market capitalisation of ₹15,144 Cr and QMS Medical Allied Services ₹333 Cr, as of 9 Nov 2026. Their P/E ratios are 89 and 31.9 respectively.
| Metric | Molbio Diagnostics | QMS Medical Allied Services |
|---|---|---|
| NSE Symbol | MOLBIO | QMSMEDI |
| BSE Code | 544866 | — |
| Share Price | ₹1,333.80 | ₹170.28 |
| Market Cap | ₹15,144 Cr | ₹333 Cr |
| P/E Ratio | 89 | 31.9 |
| Return on Equity | — | 12.29% |
| Return on Assets | 9.24% | 6.82% |
| Dividend Yield | — | 0.29% |
| Beta (1Y) | -0.17 | 0.69 |
| 1-Year Price Change | — | +76.8% |
| 3-Month Price Change | — | +52.5% |
| 52-Week Range | ₹926.35 – ₹1,686.80 | ₹68.95 – ₹216.79 |
| Latest Quarter | Q2 FY27 | Q1 FY27 |
| Quarterly Revenue | ₹259 Cr | ₹57 Cr |
| Quarterly Net Profit | ₹8 Cr | ₹4 Cr |
| Net Margin | 3.0% | 7.0% |
| EPS (Basic, Quarter) | — | ₹2.05 |
| Results Basis | consolidated | consolidated |
| Headquarters | Verna, Goa | Mumbai, Maharashtra |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Molbio Diagnostics Limited, a point-of-care diagnostics company, provides healthcare technologies to diagnose infectious and non-communicable diseases. It manufactures and sells chip based diagnostic devices, chips and reagents, X-ray equipment's, and single/dual detectors. It also offers disposable POCT devices, which includes dengue, malaria, and COVID-19 tests; Tabletop analysers, a portable machine that are used to perform molecular or immunodiagnostic tests to detect infectious diseases, such as tuberculosis, human papillomavrus, STIs, and GI disorders. In addition, the company offers Tru…
QMS Medical Allied Services Limited distributes medical and healthcare devices in India. The company also manufactures and sells glucometers, pulse oximeters, IR thermometers, BP monitors, anatomy sets, neurology kits, orthopedic aids, and weighing scales, etc.; and operates QMSMEDS, an e-commerce platform that sells healthcare devices of various brands. In addition, the company provides diagnostic and patient management services, including ambulatory blood pressure tracking, continuous blood glucose and blood pressure/glucose monitoring, tonometry, and HbA1C services. Further, it offers Educa…
Molbio Diagnostics has a market capitalisation of ₹15,144 Cr, against ₹333 Cr for QMS Medical Allied Services as of 9 Nov 2026, about 45.5 times the size by market cap.
Molbio Diagnostics has a P/E of 89 and QMS Medical Allied Services a P/E of 31.9 as of 9 Nov 2026.
Molbio Diagnostics reported revenue of ₹259 Cr and net profit of ₹8 Cr for Q2 FY27. QMS Medical Allied Services reported revenue of ₹57 Cr and net profit of ₹4 Cr for Q1 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Health Care Equipment and Supplies > Health Care Equipment > Medical Testing, Analyzing, and Diagnostic Equipment on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.